Figure 14.

Western blot analysis of the expression level of human epidermal growth factor 2 (HER2) and vascular endothelial growth factor (VEGF) in MDA-MB-468 and HME50-5E cells treated with Selenite, Trastuzumab (TZ) and Selenotrastuzumab (Se-TZ). Total cell lysates were subjected to SDS-PAGE followed by Western blotting. Membranes were probed with the anti-HER2, anti-VEGF, or anti β-actin antibodies followed by peroxidase conjugated rabbit anti-mouse antibodies and visualization was performed by the enhanced chemiluminescence (ECL) detection system. (A) HER2 and MDA-MD-468 cells. Lane 1: BT474 as HER2 positive loading control; Lanes 2 and 3: Control; Lanes 4 and 5: Selenite (2 µg as Se) treatments; Lanes 6 and 7: TZ (26.22 µg as protein) treatments; Lanes 8 and 9: Se-TZ (2 µg as Se from 26.22 µg as protein) treatments. (B) HER2 and HME50-5E. Lane 1: BT474 as HER2 positive loading control; Lane 2: Molecular weight markers; Lanes 3 and 4: Control; Lanes 5 and 6: Selenite (2 µg as Se) treatments; Lanes 7 and 8: TZ (26.22 µg as protein) treatment; Lanes 9 and 10: Se-TZ (2 µg as Se from 26.22 µg as protein) treatments. (C) VEGF and MDA-MB-468 cells. Lanes 1 and 2: Control; Lanes 3 and 4: Selenite (2 µg Se) treatments; Lanes 5 and 6: BV (30.7 µg protein) treatment; Lanes 7 and 8: Se-BV (2 µg Se from 30.7 µg protein) treatments. (D) VEGF and HME50-5E cells. Lane 1: MDA-MB-468 as VEGF positive loading control; Lanes 2 and 3: Control; Lanes 4 and 5: Selenite (2 µg Se) treatments; Lanes 6 and 7: BV (30.7 µg protein) treatment; Lanes 8 and 9: Se-BV (2 µg Se from 30.7 µg protein) treatments.